And we still don't see any directors buying at the current...

First 12 Last

Share
Profile

Follow
SMXtimes50folds

4,705 Posts.

521

14/10/22

17:51

Post #: 64207477
Share

Originally posted by T.E.P.: ↑

Danny's post is a little tone-deaf to the shareholders who enabled that 26x increase in revenue and who are suffering.

He mentions revenue growth but not growth in shares on issue... as a CEO of a listed company, his performance should be anchored to the share price, or at the very least revenue per share, not revenue alone.

I firmly disagree that it is too late for this company. In fact, they are now in the strongest position they have ever been in since listing, and I also firmly disagree that profits should have been the main focus in the early years.

Scaling a contract manufacturing business is extremely capital intensive and early shareholders have been the guinea pig of this. However, the business is now at scale with $80m run-rate revenue and is in a position to turn an NPAT profit, which I am expecting in FY23 and beyond.

With operating leverage now kicking in, NOW the focus of this company should turn to profitability and finally shareholders should be rewarded.

From here on in, there are no excuses. Going forward, with a new CEO, I want to see the share price as Jourdan Thompson's single most important measure of success. Additionally, all Directors/senior management should have at least 2x their annual base in shares, ideally 5x, to enable this alignment.

If not, the Board is not doing their job.

Expand

And we still don't see any directors buying at the current market cap?

Any thoughts on that one? Are they not buying as they don't believe the SP will appreciate overtime or are they just all have their bucket full?

HLF Price at posting: 4.8¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 12 more messages in this thread...

First 12 Last

Add HLF (ASX) to my watchlist

And we still don't see any directors buying at the current...

Top Stories

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News